Back to Search
MATTHEW GALSKY, MD
MD
Medical Oncology Physician
NPI: 1639140668IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
220970(NY)
Education
TUFTS UNIVERSITY SCHOOL OF MEDICINE
Class of 1998
Research & Publications (20)
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
PMID 18362364·J Clin Oncol·2008
3-trial
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
PMID 17200962·Cancer·2007
3-trial
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
PMID 17320659·Urology·2007
3-trial
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
PMID 17146733·Invest New Drugs·2007
3-trial
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
PMID 15735119·J Clin Oncol·2005
3-trial
The development of differentiation agents for the treatment of prostate cancer.
PMID 14571416·Semin Oncol·2003
6-review
Use of nomograms for predicting survival in patients with castrate prostate cancer.
PMID 14747049·Urology·2003
6-review
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
PMID 19633050·Ann Oncol·2010
3-trial
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
PMID 19262991·Invest New Drugs·2010
8-other
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
PMID 19403937·Ann Oncol·2009
8-other
Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis.
PMID 19349386·Chest·2009
8-other
Trial design for metastatic castration-resistant prostate cancer.
PMID 18640946·J Clin Oncol·2008
8-other
Current optimal chemotherapy for advanced urothelial cancer.
PMID 18095883·Expert Rev Anticancer Ther·2008
6-review
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.
PMID 17941029·Cancer·2007
6-review
Outcomes and prognosis in advanced renal cell carcinoma.
PMID 17555394·Expert Rev Anticancer Ther·2007
6-review
High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?
PMID 17297500·Nat Clin Pract Urol·2007
8-other
Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
PMID 17239282·Clin Genitourin Cancer·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10 E 102ND ST
NEW YORK, NY 10029 - Phone
- (212) 241-6756
Quick Facts
- NPI
- 1639140668
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile